TY - JOUR T1 - No indication of insulin resistance in idiopathic PAH with preserved physical activity JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01228-2019 SP - 1901228 AU - Bence M. Nagy AU - Gabor Kovacs AU - Adrienn Tornyos AU - Eva Svehlikova AU - Vasile Foris AU - Chandran Nagaraj AU - Grazyna Kwapiszewska AU - Thomas R. Pieber AU - Andrea Olschewski AU - Horst Olschewski Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/02/20/13993003.01228-2019.abstract N2 - There is growing interest in metabolic profiling in pulmonary arterial hypertension (PAH) due to current findings suggesting significant metabolic changes causing pulmonary arterial remodelling and linking PAH to insulin resistance [1]. Such findings may have major impact on future diagnostic and therapeutic strategies for PAH. However, most of the studies have enrolled patients with severe disease whose reduced physical activity may have a profound effect on insulin sensitivity.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Nagy has nothing to disclose.Conflict of interest: Dr. Kovacs reports personal fees and non-financial support from Actelion, personal fees and non-financial support from Bayer, personal fees and non-financial support from GSK, personal fees and non-financial support from MSD, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Novartis, personal fees and non-financial support from Chiesi, non-financial support from VitalAire, non-financial support from AOP, outside the submitted work.Conflict of interest: Dr. Tornyos has nothing to disclose.Conflict of interest: Dr. Svehlikova has nothing to disclose.Conflict of interest: Dr. Foris reports non-financial support from Actelion, non-financial support from AstraZeneca, personal fees from Bayer, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GSK, personal fees and non-financial support from MSD, non-financial support from Novartis, non-financial support from BMS, personal fees from Gerrot Lannach, non-financial support from Chiesi, outside the submitted work.Conflict of interest: Dr. Nagaraj has nothing to disclose.Conflict of interest: Dr. Kwapiszewska has nothing to disclose.Conflict of interest: Dr. Pieber has nothing to disclose.Conflict of interest: Dr. Olschewski has nothing to disclose.Conflict of interest: Dr. Olschewski reports personal fees and non-financial support from Bayer, grants, personal fees and non-financial support from Actelion, personal fees and non-financial support from MSD, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Novartis, grants from Inventiva, personal fees from Bellerophon, outside the submitted work; and Horst Olschewski is part time employee of Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria. ER -